



(11) **EP 4 227 321 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 54

(51) International Patent Classification (IPC):
C07K 16/30 ^(2006.01) **A61K 39/395** ^(2006.01)
A61P 35/02 ^(2006.01)

(48) Corrigendum issued on:
27.09.2023 Bulletin 2023/39

(52) Cooperative Patent Classification (CPC):
A61K 39/39566; A61P 35/02; C07K 16/3061;
A61K 2039/505; C07K 2317/56

(43) Date of publication:
16.08.2023 Bulletin 2023/33

(21) Application number: **22156205.1**

(22) Date of filing: **10.02.2022**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(71) Applicant: **AVA Lifescience GmbH**
79211 Denzlingen (DE)
(72) Inventor: **DÜHREN-VON MINDEN, Marcus**
79379 Müllheim (DE)
(74) Representative: **Cacace, Sabrina Rosella**
Immentalstraße 38
79104 Freiburg (DE)

(54) **ANTIBODIES TARGETING THE B-CELL RECEPTOR OF CHRONIC LYMPHOCYTIC LEUKEMIA AND USES THEREOF**

(57) The present invention provides antibodies for the treatment of chronic lymphocytic leukemia (CLL). These antibodies target the B-cell receptor (BCR) of CLL cells characterised by R110-mutated immunoglobulin lambda variable 3-21 (IGLV3-21^{R110}).

The invention also provides nucleic acid sequences encoding the forgoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

EP 4 227 321 A8